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 2 
Abstract 1 
Papillary thyroid carcinoma (PTC) etiologically occurs as a radiation-induced or sporadic malignancy. 2 
Genetic factors contributing to the susceptibility to either form remain unknown. In this retrospective 3 
case-control study we evaluated possible associations between single nucleotide polymorphisms (SNPs) 4 
in the candidate DNA damage response genes (ATM, XRCC1, TP53, XRCC3, MTF1) and risk of 5 
radiation-induced and sporadic PTC. A total of 255 PTC cases (123 Chernobyl radiation-induced and 132 6 
sporadic, all in Caucasians) and 596 healthy controls (198 residents of Chernobyl areas and 398 subjects 7 
without history of radiation exposure, all Caucasians) were genotyped. The risk of PTC and SNPs 8 
interactions with radiation exposure were assessed by logistic regressions. The ATM G5557A and XRCC1 9 
Arg399Gln polymorphisms, regardless of radiation exposure, associated with a decreased risk of PTC 10 
according to the multiplicative and dominant models of inheritance (OR=0.69, 95% CI 0.45-0.86 and 11 
OR=0.70, 95% CI 0.59-0.93, respectively). The ATM IVS22-77 T>C and TP53 Arg72Pro SNPs 12 
interacted with radiation (P=0.04 and P=0.01, respectively). ATM IVS22-77 associated with the increased 13 
risk of sporadic PTC (OR=1.84, 95% CI 1.10-3.24) whereas TP53 Arg72Pro correlated with the higher 14 
risk of radiogenic PTC (OR=1.80, 95% CI 1.06-2.36). In the analyses of ATM/TP53 15 
(rs1801516/rs664677/rs609429/rs1042522) combinations, the GG/TC/CG/GC genotype strongly 16 
associated with radiation-induced PTC (OR=2.10, 95% CI 1.17-3.78). The GG/CC/GG/GG genotype 17 
displayed a significantly increased risk for sporadic PTC (OR=3.32, 95% CI 1.57-6.99). The results 18 
indicate that polymorphisms of DNA damage response genes may be potential risk modifiers of IR-19 
induced or sporadic PTCs. 20 







Introduction  1 
Thyroid cancer accounts for more than 90% of all endocrine malignancies. The incidence of 2 
thyroid cancer in the world is increasing during the past three decades, mainly due to the papillary thyroid 3 
carcinoma (PTC) which is the predominant type of malignant thyroid tumors (Davis & Welch 2006).  4 
Most thyroid cancer patients do not have history of radiation exposure, yet ionizing radiation (IR) 5 
is a recognized etiological factor of the disease. An increased risk of thyroid cancer has been documented 6 
after external irradiation (Ron et al. 1995) and after environmental exposure to 
131
I, such as after the 7 
Chernobyl fallouts in Belarus, Ukraine and Russia (Bennett et al. 2006).  8 
Although radiation thyroid doses in Chernobyl PTC cases are generally greater than in controls in 9 
epidemiological studies (Cardis et al. 2005; Jacob et al. 2006; Likhtarev et al. 2006), thus confirming 10 
radiation to be a risk factor for thyroid cancer, those in controls are nonzero. Furthermore, there were 11 
some 14 million residents in the contaminated territories at the time of exposure (Bennett et al. 2006). 12 
Conceivably, at least some of them might have accumulated thyroid doses comparable to doses in 13 
diseased individuals. However, thyroid cancer developed only in a small fraction of irradiated population.  14 
Among the variety of DNA damage types induced by radiation, double-strand DNA breaks are 15 
considered to be the most significant for chromosomal aberrations, mutagenesis, genetic instability and 16 
carcinogenesis (Khanna & Jackson 2001). PTC is one of the rare human cancers of epithelial origin in 17 
whose oncogenesis gene rearrangements play a noticeable role. Several variants of rearrangements are 18 
described in PTC, with RET/PTC occurring most frequently (Nikiforov et al. 1997; Rabes et al. 2000).  19 
While in the exposed individuals DNA damage could be attributed to ionizing radiation, the 20 
origination of genetic alterations in sporadic cancers remains obscure. Nevertheless, the spectrum of 21 
oncogenic changes in radiation-related and sporadic PTCs is largely common. Such similarities imply the 22 
resemblance of molecular reactions on DNA damage in exposed and non-exposed thyrocytes. These 23 
reactions involve first of all DNA damage response factors, including DNA repair and checkpoint 24 
complexes.  25 
 4 
The vast majority of Chernobyl thyroid malignancies were PTCs which displayed wide variations 1 
in clinical course, from highly aggressive tumors developing after the shorter latency to more indolent 2 
carcinomas with the longer latent period (Williams 2006). The randomness and multiplicity of forms of 3 
genetic alterations caused by IR can only partly explain these differences in the individual reactions on 4 
exposure as well as why cancer develops only in some of exposed individuals.  5 
It is attractive to hypothesize that inherited variability in the genes directly or indirectly involved 6 
in the maintenance of genome stability in response to environmental carcinogens such as IR or chemicals 7 
may play a role in susceptibility for radiation-related or sporadic PTC or may be a marker of it. In this 8 
work we tested the relation of genetic variants of some of such genes, namely ATM, TP53, XRCC1, 9 
XRCC3 and MTF1, to PTC of different etiology.  10 
The Ataxia-telangiectasia mutated (ATM) gene plays a key role in the sensing and repair of DNA 11 
double-strand breaks. Activation of the ATM protein kinase by IR results in the subsequent initiation of 12 
several molecular pathways of DNA damage repair (Shiloh 2003). One of the ATM targets is the p53 13 
pathway. Overexpression of TP53 arrests the cell cycle and affects DNA repair and apoptosis.  14 
The ATM and TP53 genes play a significant role especially in the tumors that are induced by IR. 15 
A number of single nucleotide polymorphisms (SNPs) in the ATM and TP53 genes studied in populations 16 
of different ethnicities have been reported to associate with the risk of different radiogenic tumors (Hu et 17 
al. 2002; Angele et al. 2003; Thorstenson et al. 2003; Malmer et al. 2007). In contrast, studies of post-18 
Chernobyl pediatric thyroid cancers demonstrated a low mutation and polymorphism rate in the TP53 19 
gene (Nikiforov et al. 1996; Hillebrandt et al. 1997). It, however, should be mentioned that after exposure 20 
to radiation p53 facilitates DNA repair in normal thyrocytes in vitro (Yang et al. 1997). 21 
The base excision repair (BER) and homologous recombination repair (HRR) pathways are 22 
particularly important for genomic integrity restoration (Hoeijmakers 2001). The product of the X-ray 23 
repair cross complementing 1 (XRCC1) gene acts as a scaffold and a modulator of different enzymes 24 
involved in BER. The XRCC1 Arg399Gln and Arg280His variants have been extensively investigated for 25 
their function and association with cancer risk; however, the results remain contradictory rather than 26 
 5 
conclusive (Hu et al. 2005). The XRCC3 gene is a member of the Rad51 DNA-repair gene family. Its 1 
product is a factor of the HRR. The XRCC3 Thr241Met polymorphism has been controversially 2 
associated with different human malignancies (Han et al. 2006).
 
Sturgis et al. (2005) reported 241Met 3 
allele association with the risk of differentiated thyroid cancer . 4 
 The Metal-responsive transcription factor1 (MTF1) gene has been implicated in tumor initiation 5 
and progression to malignant growth. MTF1 protein interacts with metallothioneins that are able to 6 
suppress cellular stresses generated by IR and other agents (Tamura et al. 2005). Polymorphism in murine 7 
Mtf1 gene has been found to associate with the susceptibility to experimental γ-ray-induced thymic 8 
lymphomas. This observation points at possible involvement of human MTF1 polymorphisms in the 9 
modulation of radiation-induced malignancies (Tamura et al. 2005). 10 
 To date no polymorphisms of the ATM, XRCC1 and MTF1 genes have been studied neither in 11 
human sporadic or radiation-induced PTCs. Data on the TP53 and XRCC3 polymorphisms associations 12 
are quite limited (Hillebrandt et al. 1997; Boltze et al. 2002; Granja et al. 2004; Sturgis et al. 2005; 13 
Rogounovitch et al. 2006). Therefore, in this study we addressed the relation of SNPs in aforementioned 14 
DNA damage response genes to the risk of PTCs of different etiology.  15 
 16 
Materials and methods 17 
Study population 18 
 A total of 255 histologically verified PTC cases and 596 healthy controls, all Caucasians, were 19 
included in the study. Among the patients, 123 individuals with PTC (24 males and 99 females) lived in 20 
the areas of the Russian Federation (38 patients) and Belarus (85 patients) contaminated with 21 
radionuclides from Chernobyl fallouts. At the time of the Chernobyl accident these subjects were younger 22 
than 18 years old (mean age at exposure ± SD, 9.8 ± 5.1 years old; 1-18 years old, range). The mean age 23 
at diagnosis was 24.4 ± 4.9 years old, range 19-37 years old (IR-induced PTCs). Information about 24 
individual radiation thyroid doses was available for PTC cases from Russia as reconstructed in previous 25 
studies (Davis et al. 2004; Stepanenko et al. 2004). The doses varied from 43 to 2640 mGy. Radiation 26 
 6 
thyroid doses for PTC patients and controls from Belarus evaluated in dosimetric investigations at the 1 
places of residence ranged 21–1500 mGy (Bouville et al. 2007). Among the controls, 198 individuals (65 2 
males and 133 females, mean age at sampling 22.2 ± 3.2 years old; 19-35 years old, range) were residents 3 
of the Chernobyl areas (60 from the Russian Federation and 138 from Belarus). The averaged thyroid 4 
radiation dose in the exposed control subjects from Russia is 41 mGy (Bouville et al. 2007). All exposed 5 
control individuals were aged less than 18 years at the time of the accident (mean age at exposure 1.8 ± 6 
3.2 years old; 1-16 years old, range) (IR-exposed controls). IR-exposed controls and patients with IR-7 
induced PTCs not were individually matched; however, they were residents of the same settlements. This, 8 
given the uncertainty with individual radiation thyroid doses, was supposed to partly reduce exposure bias. 9 
Age of IR-exposed control subjects was set to be ± 3 years of that of IR-induced PTC individuals.  10 
One hundred and thirty-two PTC cases (21 males and 111 females, mean age at diagnosis 47.8 ± 11 
11.4 years old; 19-76 years old, range) were adults without history of radiation exposure (sporadic PTCs). 12 
The remaining 398 control participants (180 males and 218 females, mean age at sampling 45.0 ± 10.3 13 
years old; 16-65 years old, range) had no previous history of radiation exposure (non-exposed controls); 14 
their age was also set to be ± 3 years of that of patients with sporadic PTC. Both sporadic PTCs and non-15 
exposed controls originated from the European part of Russia not contaminated by the Chernobyl fallouts.  16 
Thyroid tissues and/or blood samples were collected from patients during surgery or further 17 
follow-up. Blood samples and information from the controls were obtained during a routine health 18 
examination or complex screening for thyroid diseases.  19 
Written informed consent was obtained from all participants. Protocols of the present study were 20 
approved by the Committee for Ethical Issues of Human Genome Analysis of Nagasaki University.  21 
 22 
SNP selection  23 
The candidate SNPs (Table 1) were selected based on their reported functional role (if available), 24 
associations with radiosensitivity or (thyroid) cancer risk. Accordingly, we did not search for tag SNPs or 25 
account for the genetic variability in the regions of SNP location. All SNPs are listed in a public database, 26 
 7 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), with validated status in ethnically diverse populations. To 1 
ensure sufficient power for calculations, only SNPs with minor allele frequency (MAF) of >1% were 2 
included. 3 
 4 
SNP genotyping  5 
DNA was extracted from normal thyroid tissues using proteinase K/phenol-chloroform method or 6 
from the whole blood lymphocytes with Puregene
 
DNA Purification Kit (Gentra Systems, Inc., 7 
Minneapolis, PA, USA). All specimens were genotyped using various techniques (Table 1). Primers and 8 
probes (Table 2) were designed with Primer Express Version 1.0 (Applied Biosystems, Foster City, CA, 9 
USA) software.  10 
 Briefly, 25 µl PCR mixtures generally contained 50 ng DNA, 1.5 mM MgCl2, 200 µM each dNTP, 11 
optimized concentrations of corresponding primers and 0.625 U of AmpliTaq Gold (Applied Biosystems, 12 
Foster City, CA, USA). All restriction endonucleases for PCR/RFLP were from New England BioLabs 13 
(Ipswich, MA, USA). TaqMan allelic discrimination assay for TP53 variants was done essentially as 14 
described before (Rogounovitch et al. 2006). Melting curve Tm-shift assay for MTF1 genotyping was 15 
designed according to the described technology (Wang et al. 2005) and done in a Thermal Cycler Dice
 16 
Real Time System TP800 (TaKaRa, Ohtsu, Japan). Technical details are available from the authors upon 17 
request.  18 
For every SNP, some 20-30 randomly chosen DNA samples, unless otherwise specified, were 19 
also analyzed by direct sequencing with a Big Dye Terminator sequencing kit v3.1 (Applied Biosystems, 20 
USA) in an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, USA). A complete concordance 21 
between different techniques was observed. 22 
Raw genotyping outputs were interpreted by at least two independent investigators. Missing 23 
results due to genotyping procedure failures accounted for <1% for any SNP tested. 24 
 25 
Statistical analysis 26 
 8 
Genotype frequencies in each group were determined by univariate analysis and evaluated for 1 
departure from Hardy-Weinberg equilibrium by the chi-square test. SNP associations with PTC were 2 
assessed by multivariate logistic regression analysis for codominant, multiplicative, dominant and 3 
recessive models to avoid assumptions regarding the mode of inheritance (see notes below Table 4). All 4 
analyses were adjusted for gender (male or female, nominal), age (years, continuous) and IR-exposure 5 
(yes or no, nominal). Besides of all of the parameters above, the full model included disease status (yes or 6 
no, nominal) and, depending on the mode of inheritance, genotype for each SNP (nominal variable in the 7 
codominant, dominant and recessive models and ordinal in the multiplicative model).  8 
 Power calculations were done with the PS software 9 
(http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). With given sample size, the 10 
study had a power of 54-99 % to detect an OR of 2.0 at the significance level of 5% with MAF ranging 4-11 
45%. 12 
Interaction between SNPs, cancer and radiation exposure were hypothesized a priori and 13 
evaluated by multivariate analysis with corresponding adjustments. Separate calculations of OR were 14 
done in irradiated and non-exposed case-control groups when P value for an interaction term did not 15 
exceed 0.05. 16 
 Statistical analysis was done using SPSS for Windows version 17.0 (SPSS, Inc., Chicago, IL, 17 
USA).  18 
 19 
Results 20 
The distribution of genotypes and MAF for each SNP in the four study groups is shown in Table 21 
3. The observed distributions in the control groups were not statistically different from those expected 22 
from Hardy-Weinberg equilibrium for all SNP except for ATM G5557A and ATM IVS22-77 T>C in the 23 
non-exposed controls. Since such deviation might point at possible genotyping error (Hosking et al. 2004), 24 
we reanalyzed 96 non-exposed controls for these SNPs by direct sequencing. There were no 25 
inconsistencies between PCR/RFLP and sequencing results (data not shown) ruling out technical flaw. 26 
 9 
Furthermore, allelic frequencies determined in our study are in a good agreement with those specified for 1 
Caucasians in the dbSNP (build 129, April 2008, Table 1) thus attesting to the appropriate data quality. 2 
As seen from Table 4, an association between ATM G5557A and PTC, regardless of radiation 3 
exposure, was found. The presence of the A allele significantly decreased PTC risk compared with wild-4 
type G allele in the multiplicative model of inheritance (OR=0.69, 95% CI 0.45-0.86, P=0.03), which is 5 
useful for risk comparison between the groups based on the analysis of allelic frequencies in them.  6 
Main effect on PTC risk appeared also significant for the XRCC1 gene Arg399Gln polymorphism. 7 
The presence of the minor 399Gln allele decreased PTC risk compared with the Arg/Arg genotype 8 
(OR=0.66, 95% CI 0.57-0.88, P=0.02 and OR=0.70, 95% CI 0.59-0.93, P=0.03, in the co-dominant and 9 
dominant models, respectively).  10 
Analysis of combined ATM G5557A and XRCC1 Arg399Gln genotypes demonstrated that 11 
increasing number of minor alleles (i.e. ATM 5557A and XRCC1 399Gln) significantly decreased PTC 12 
risk in corresponding individuals in comparison with those who do not carry minor alleles (Fig. 1). 13 
No other SNP in any gene showed a significant main effect on PTC. 14 
For ATM IVS22-77 T>C and TP53 Arg72Pro, evidence for interaction between radiation 15 
exposure and PTC was found (P for interaction 0.04 and 0.01, respectively). As shown in Table 5, the 16 
analyses performed in IR-exposed and non-irradiated patients compared, respectively, with irradiated and 17 
non-exposed controls revealed a significantly increased risk of sporadic PTC for the ATM IVS22-77 18 
homozygous CC genotype carriers compared with the TC+TT genotypes (the recessive model of 19 
inheritance, OR=1.84, 95% CI 1.10-3.24, P=0.03), whereas in the irradiated group an insignificant 20 
inverse effect of these genotypes was observed (OR=0.59, 95% CI 0.28-1.27, P=0.17). For TP53 codon 21 
72 polymorphism, in all but the recessive models the increased risk of IR-induced PTC as compared to 22 
IR-exposed controls was observed. The highest risk of radiogenic PTC was in the co-dominant model 23 
(OR=2.33, 95% CI 1.15-7.21, P=0.03). A significant risk was also found in the multiplicative model of 24 
inheritance (OR=1.70, 95% CI 1.17-2.46, P=0.006). In addition, comparison between IR-exposed and 25 
non-exposed controls did not reveal statistically significant difference in adjusted distributions of these 26 
 10 
polymorphisms. In healthy subjects the strongest association for the ATM IVS22-77 T>C was in the 1 
recessive model (OR=1.38, 95% CI 0.84-2.26, P=0.21) and in the multiplicative model for TP53 2 
Arg72Pro (OR=0.70, 95% CI 0.52-1.19, P=0.11) further emphasizing possible role of these SNPs in PTC 3 
of different etiology.  4 
Considering multiple pathways for repairing diverse DNA damages induced by endogenous and 5 
exogenous carcinogens, genetic variants in different repair pathways may probably have a joint effect on 6 
cancer risk. In attempt to search for the stronger associations between PTC and studied SNPs, we 7 
performed the analyses of genotype combinations for the ATM and TP53 polymorphisms as these genes 8 
are functionally related and 3 of 4 SNPs included in our study showed effects on PTC. Among the 9 
possible ATM/TP53 combinations (rs1801516/rs664677/rs609429/rs1042522) tested, two demonstrated 10 
significant differences in the subsets of both groups of PTCs (Fig.2). Particularly, the combined 11 
ATM/TP53 GG/TC/CG/GC genotype was strongly associated with the IR-induced PTC (OR=2.10, 95% 12 
CI 1.17-3.78, P=0.015). Another ATM/TP53 combination, GG/CC/GG/GG, demonstrated a significantly 13 
increased risk for sporadic PTC (OR=3.32, 95% CI 1.57-6.99, P=0.002).  14 
 15 
Discussion 16 
Our study addressed possible associations between SNPs in the genes involved in DNA damage 17 
response and the risk of PTC of different etiology. The results demonstrated that the presence of the 18 
variant 5557A allele in exon 39 of ATM and XRCC1 399Gln allele, particularly in the heterozygous state, 19 
significantly associated with the decreased risk of PTC. The ATM IVS22-77 CC genotype in the non-20 
exposed group and the TP53 72Pro allele in the radiation-related one associated with the increased risk of 21 
PTC. Moreover, two particular ATM/TP53 combined genotypes were found with higher frequencies in the 22 
IR–induced or sporadic PTC when compared to the controls. Altogether, these data indicate that SNPs in 23 
the studied genes may likely modify PTC risk.  24 
A significant association between the ATM G5557A and bilateral breast cancer in Caucasian 25 
patients has been shown before (Heikkinen et al. 2005). Also, this SNP has been reported as a possible 26 
 11 
modulator of clinical radiosensitivity in cancer. The ATM 5557A allele was associated with severe 1 
adverse effects of radiation therapy in prostate (Hall et al. 1998) and breast cancer patients (Angele et al. 2 
2003). Later, an enhanced radiosensitivity of human fibroblasts in the presence of the ATM 5557A allele 3 
was demonstrated in an experimental work (Alsbeih et al. 2007). In contrast to these reports, Edvardsen et 4 
al. (2007) revealed an increasing rate of side effects of radiotherapy with decreasing frequency of this 5 
variant allele. Our data are rather in agreement with the latter report and favor the protective role of the 6 
ATM 5557A allele in PTC development.  7 
The intronic ATM polymorphisms IVS22–77 T>C and IVS48+238 C>G in the homozygous state 8 
have been associated with increased breast cancer risk and in the heterozygous state with clinical 9 
radioprotection (Angele et al. 2003). These findings were confirmed in the in vitro experiments using 10 
lymphoblastoid cell lines established from corresponding patients. Our investigation demonstrated the 11 
association between the IVS22–77 CC genotype and increased risk of sporadic PTC in adult patients. By 12 
contrast, in the IR-induced PTC group, there was an inverse non-insignificant correlation for this 13 
genotype. At the same time, in the IR-induced PTCs, the number of patients heterozygous for IVS22–77 14 
was somewhat, but insignificantly, higher as compared to sporadic PTCs (Table 3). The results for the 15 
IVS48 + 238 C>G tended to parallel those for the IVS22–77 T>C remaining below the threshold of 16 
significance. At present, the mechanistic and functional basis for the intronic ATM SNPs implications in 17 
cancer revealed in the previous studies and in ours as well is not fully understood. In a broader sense, 18 
however, they may be indicative of a role for the ATM gene (or its product) in the development of PTC. 19 
As reviewed by Hu et al. (2005), the results of the XRCC1 gene Arg399Glu investigations vary in 20 
different cancers for populations with different ethnicities. In relation to cancer and radiation, the 399Gln 21 
allele in combination with 280His was associated with breast cancer risk, and in pair with 194Trp with 22 
clinical radiosensitivity in Caucasian women with breast cancer. Also, the 399Gln allele was found to 23 
decrease the risk of bladder cancer and squamous cell carcinoma of the head and neck.  24 
Interestingly, not only variant, but also wild-type allele (i.e. XRCC1 399Arg) demonstrated 25 
possible role in cancer. High-dose radiation to the chest was more strongly associated with breast cancer 26 
 12 
among white American women with XRCC1 Arg399Arg genotype (Duell et al. 2001). Looking for 1 
potential biological explanations for these findings, the authors found a higher prevalence of TP53 2 
deletions in the Arg399Arg cases exposed to occupational radiation compared with exposed patients with 3 
the Gln399Gln genotypes or unexposed cases of either genotype. Figueiredo et al. (2004) observed an 4 
increased risk of disease among wild-type homozygous (Arg/Arg) and heterozygous Canadian Caucasian 5 
women with a family history of breast cancer compared to the individuals without such.  6 
The described above data may be explained, at least in part, by the results of functional study of 7 
this polymorphism in which an equal ability for both alleles to suffice single strand break repair by 8 
XRCC1 has been found (Taylor et al. 2002). The results of our study, taken together with those reported 9 
previously, suggest that XRCC1 polymorphism, in particular the Arg399Gln genotype, may influence 10 
PTC risk, perhaps by modifying the effects of environmental exposure and/or through interaction with 11 
other genetic factors.  12 
The TP53 Arg72Pro polymorphism affects the biological activity of p53. The Arg72 form is more 13 
efficient at inducing apoptosis while the Pro72 appears to induce a higher level of G1 arrest (Pim & 14 
Banks 2004). Based on these findings, a number of studies have attempted to assess a correlation between 15 
TP53 codon 72 polymorphism and risk of certain types of cancer, however, with inconsistent results, as 16 
reviewed by Pietsch et al. (2006). This inconsistency may possibly be explained in part by the coexistence 17 
of the codon 72 polymorphism and gain of function mutations in TP53 in some tumors (Pietsch et al. 18 
2006; Soussi & Wiman 2007).  19 
Several groups have investigated the TP53 Arg72Pro polymorphism in PTC. Boltze et al. (2002) 20 
found a small number of heterozygotes and no Pro/Pro genotype in differentiated thyroid carcinomas 21 
from Germany. In contrast, in ethnically heterogeneous Brazilian population, the Pro/Pro genotype was 22 
associated with the higher risk of differentiated thyroid cancer (Granja et al. 2004). The study of codon 72 23 
polymorphism in thyroid tumors from Russian and Ukrainian patients demonstrated a significantly lower 24 
frequency of wild-type homozygotes (i.e. Arg/Arg) among adults with IR-induced PTC when compared 25 
with sporadic PTC cases and general population (Rogounovitch et al. 2006). Data obtained in the present 26 
 13 
work, using an independent set of samples, confirm these findings suggesting the modifying role (or as of 1 
a marker) of the TP53 Arg72Pro polymorphism in PTC developed after exposure to IR which is further 2 
supported by the absence of significant difference in genotype distributions among our two control groups. 3 
 As shown in a genetic study, frequencies of the C allele (encoding 72Pro) do not generally differ 4 
in populations of Belarus and Russia (Khrunin et al. 2005). However, East Slavs do not form a single 5 
genetic cluster on multidimensional analysis. The 72Pro allele frequency in Belarus is about 0.3; in the 6 
two different subpopulations from the Central and Northern regions of the European part of Russia it is 7 
0.24 and 0.32, respectively. The study of healthy population from Poland (bordering with Belarus, 8 
linguistically and culturally similar), reported the frequency of 0.28 for the 72Pro allele (Siddique at al. 9 
2005). The 72Pro frequency reported by Rogounovitch et al. (2006) in Russian healthy controls is also 10 
0.28. Thus, the effect of population admixtures in the controls in our investigation could not be 11 
completely ruled out. Yet on the other hand, the ratio of Belarusian and Russian subjects in the IR-12 
exposed PTCs and controls was similar (2.24 and 2.30, respectively) suggestive of an unbiased estimate 13 
and being an argument in support of TP53 Arg72Pro polymorphism association with radiation-related 14 
PTC. 15 
While many studies established the effect of individual SNPs on cancer, the role of SNP 16 
combinations has been less addressed. Several ATM and TP53 haplotypes were associated with clinical 17 
radiosensitivity in breast cancer (Angele et al. 2003) and brain tumor risk (Malmer et al. 2007). Recently, 18 
the interactions of SNPs located on different chromosomes were investigated in various malignancies 19 
(Yen et al. 2008; Yoon et al. 2008). One experimental study, in which ATM Asp1853Asn, TP53 20 
Arg72Pro, XRCC1 Arg399Gln and XRCC3 Thr241Met were genotyped, demonstrated that the increasing 21 
number of risk alleles enhanced radiosensitivity of human fibroblast cell lines and, potentially, 22 
susceptibility to radiation-induced cancers (Alsbeih et al. 2007). So far no studies have investigated the 23 
joint effect of gene polymorphisms on thyroid cancer. Our observations demonstrated that frequencies of 24 
particular combined ATM/TP53 genotypes were higher in patients with radiogenic or sporadic PTC 25 
compared to corresponding control populations. 26 
 14 
To some extent these results support the idea that genetic factors may possibly modify 1 
predisposition to thyroid cancer. A recent study by Detours et al. (2007) reported difference in the 2 
expression levels of some genes between Chernobyl PTCs from Ukraine and French sporadic PTCs. 3 
Although the mentioned work and the present one used different molecular approaches, the results of both 4 
are suggestive of a possible genetic “susceptibility signature” that may contribute to the individual 5 
predisposition to IR and other carcinogens’ effects. These findings are in favor of a “susceptibility model” 6 
that may partly explain why only a minority of the large population exposed to the IR after the Chernobyl 7 
disaster developed thyroid cancer (Yamashita & Saenko 2006; Detours et al. 2007; Detours et al. 2008).  8 
It is necessary to note that even though 9 SNPs were analyzed in our study, no correction for 9 
multiple comparisons was applied because of study design and techniques employed. The associations 10 
were tested in a one-at-a-time fashion in a limited sample size in the difficult to access groups. The need 11 
for correction in such circumstances is still debated (Rothman & Greenland 1998). Furthermore, since 12 
data obtained in this work may be referred to as an initial screening result, non-adjusted presentation 13 
enables their inclusion in future meta-analysis. Effects of candidate SNPs which we report need validation 14 
in other studies. 15 
In conclusion, the results presented here show that SNPs in ATM exon 39 and XRCC1 exon 10 16 
may be the markers of a decreased PTC risk in adults, whereas the ATM IVS22-77 and TP53 codon 72 17 
SNPs genes may associate with the risk of PTC development in non-irradiated and irradiated individuals. 18 
To the best of our knowledge, presented here is the first study of this kind reporting the results of 19 
genotyping of candidate DNA damage response genes in irradiated and non-irradiated PTC patients and 20 
in corresponding healthy populations. Our data support the paradigm of genetic modifiers of radiation-21 
associated carcinogenesis and perhaps may contribute to genetic determination of PTC-prone subjects. 22 
We believe such identification will allow future personalized cancer risk prediction which is of a 23 
significant importance in view of the growing thyroid cancer incidence and also because of the relevance 24 
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exon or intron 











GG (187, 30) 
GA (217, 187,30) 
AA (217) 
11/exon 39 European: 7-22 
Asian: 0-2 
Global: 5  
Alters an exonic splicing enhancer, modulates 
correct splicing of exon 39 (Thorstenson et al. 
2003) 
Decreases ATM expression level and capacity of 
DNA damage recognition (Heikkinen et al. 2005) 
ATM IVS22-77 T>C 
T60136C 
rs664677 PCR/RFLP (RsaI) 
TT (299) 
TC (299, 265, 34) 
CC (265, 34) 




ATM IVS48+238 C>G 
C113450G 
rs609429 PCR/RFLP (KpnI) 
CC (172, 35) 
CG (207, 172, 35) 
GG (207) 
11/intron 48 European: 60 
Asian: 37 
Global: 53 
Generates a week additional donor splice site and 
decreases gene expression (Angele et al. 2003)  
XRCC1 G25211A 
Arg280His 
rs25489 PCR/RFLP (RsaI) 
GG (155, 123) 
GA (278, 155, 
123)  
AA (278) 
19/exon 9 European: 3-10 
Asian: 0 
Global: 7 




rs25487 PCR/RFLP (MspI) 
GG (327, 107) 
GA (434, 327, 
107) 
AA (434) 
19/exon 10 European: 30-46 
Asian: 27 
Global: 23-26 
Affects IR-induced mitotic delay and 
hypersensitivity to IR (Hu et al. 2002) 
Compromises single-strand DNA breaks repair 
(controversially) (reviewed by Taylor et al. 2002) 
TP53 G640C 
Arg72Pro 
rs1042522 TaqMan 17/exon 4 European: 23-27 
Asian: 40-51 
Global: 35 
Lower efficiency in apoptosis induction; higher 
level of G1 arrest (Pim & Banks 2004) 
XRCC3 C18067T 
Thr241Met 
rs861539 TaqMan  14/exon 7 European: 41-45 
Asian: 6-14 
Global: 22 
Decreased DNA repair capacity (reviewed by Han 
et al. 2006). 
MTF1 T2193A rs11488567 Melting curve Tm–
shift 
1/intron 1 unknown No reports 
 
 
MTF1 G20433A rs3912368 Melting curve Tm–
shift 





 Restriction enzymes, genotypes and corresponding restriction fragments sizes (bp) are indicated for the SNPs analyzed by PCR/RFLP. 
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Table 2. Primers and probes for genotyping 
 
SNP  




















































w/t allele probe (FAM): CTCCCCGCGTGGCCCC  











w/t allele probe (FAM): TCACGCAGCGTGGCCCCCAG  







MTF1 T2193A F1: GCGGGCAGGGCGGCTTAACTTTAAAACCATCAAGTCATTTTTAgA 
F2: GCGGGCTTAACTTTAAAACCATCAAGTCATTTTTAAT 















 The bases shown in lowercase are mismatches introduced to generate restriction endonuclease sites (PCR/RFLP) or to optimize allelic specificity (Tm-shift). 
The underlined 5’ portions of primer sequences correspond to GC tails in the Tm-shift method.  
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n = 132 
105 (79.5) 
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40.8 
 



















n = 198 




















 There was no homozygous (A/A) variant of XRCC1 Arg280His among all samples tested. 


































Table 4. OR (95% CI) for PTC by gene polymorphism according to different models of inheritance 
(adjusted for age, gender and radiation exposure) 
 
 
SNP Genotype OR (95% CI) P 
ATM G5557A GG 
GA 
AA 
Risk per A allele
 b
 
GA+AA vs. GG 
c
 

















ATM IVS22-77 T>C TT 
TC 
CC 
Risk per C allele 
TC+CC vs. TT 




















Risk per G allele 
CG+GG vs. CC 


























XRCC1 Arg399Gln GG 
GA 
AA 
Risk per A allele 
GA+AA vs. GG 














TP53 Arg72Pro GG 
GC  
CC 
Risk per C allele 
GC+ CC vs. GG 














XRCC3 Thr241Met CC 
CT 
TT 
Risk per T allele 
CT+TT vs. CC 
















MTF1 T2193A TT 
TA 
AA 
Risk per A allele 
TA+AA vs. TT 













MTF1 G20433A GG 
GA 
AA 
Risk per A allele 
GA+AA vs. GG 
















Codominant model of inheritance (wild-type homozygous genotype serves as the reference).  
b  




(combined heterozygous and homozygous for the minor allele vs. wild-type 
homozygous).  
d  




 The dominant and recessive models are not shown for XRCC1 Arg280His because of the absence of 









Codominant model of inheritance (wild-type homozygous genotype serves as the reference).  
b  




(combined heterozygous and homozygous for the minor allele vs. wild-type homozygous).  
d  








IR-induced PTC vs. IR-exposed controls Sporadic PTC vs. non-exposed controls 
  OR (95% CI) P 
 













































TP53 Arg72Pro GG 
GC  
CC 
Risk per C allele 
GC+ CC vs. GG 





























Fig. 1. Effect of increasing number of minor alleles (MA) for ATM G5557A and XRCC1 Arg399Gln 
(minor alleles, ATM 5557A and XRCC1 399Gln) on PTC risk. The combined genotype with 0 MA was 
used as a reference. P values for genotypes with different MA number: P1MA<0.0001; P2MA<0.01; P3-4 
MA<0.05. Carriers of 3 and 4 minor alleles were combined because of the exceedingly low number of 4 
MA carriers in both PTC and control groups.  
 
Fig. 2. The combined ATM/TP53 genotypes and risk of PTC of different etiology. The combined 
genotypes were analyzed separately in the IR-exposed and sporadic PTCs vs. corresponding control. Six 
combinations of 3 ATM and 1 TP53 SNPs (rs1801516/rs664677/rs609429/rs1042522) whose frequencies 
were higher than 5% at least in two of four subgroups are shown. In the numerical codes for any SNP, 0 – 
the genotype with no MA (i.e. homozygous wild-type); 1 – 1 MA presents (heterozygous genotype); 2 – 2 
MA present (homozygous variant genotype); first 3 numbers correspond to 3 ATM SNPs and the last one 
to TP53 polymorphism. In the figure, the GG/TT/CC/GG genotype is represented by the “0000” 
numerical code as it does not contain minor alleles; the GG/TC/CG/GG corresponds to 0110, 
GG/TC/CG/GC to 0111; GG/CC/GG/GC to 0221; GA/TC/CG/GG to 1110 and GG/CC/GG/GG to 0220. 


























Proportion of MA carriers (%) 
                PTCs                            43.0                        34.4                          19.4                         3.2 



























































Proportion of carriers, (%)    IR   Sp      IR     Sp      IR     Sp      IR   Sp      IR   Sp      IR    Sp      IR     Sp 
          PTCs                          7.3  9.0     17.8 17.4    24.8 15.5    5.0  7.1     4.0  3.8     3.3  11.6    38.0  35.6 
          Controls                     9.3  8.0     21.7 17.5    13.5 14.2    7.1  3.3    10.0 5.2     6.2   3.8     32.0  48.0 
 
■  IR PTCs vs. IR control 
□  Sp PTCs vs. Sp control 
